NCT02858869View on ClinicalTrials.gov

Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

October 4, 2016

Primary Completion Date

November 19, 2020

Study Completion Date

October 28, 2023

Conditions
Metastatic Malignant Neoplasm in the BrainMetastatic MelanomaMucosal MelanomaOcular MelanomaStage IV Non-Small Cell Lung CancerStage IV Skin MelanomaMelanoma of Unknown Primary
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

RADIATION

Stereotactic Radiosurgery

Undergo SRS

Trial Locations (1)

30322

Emory University/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Emory University

OTHER

NCT02858869 - Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | Biotech Hunter | Biotech Hunter